Cadrenal Therapeutics to Participate in the 2023 BIO International Convention in BostonPRNewsWire • 06/01/23
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor ConferencePRNewsWire • 05/09/23
Cadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient PopulationPRNewsWire • 03/09/23
Cadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023PRNewsWire • 02/08/23
Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public OfferingPRNewsWire • 01/24/23
Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial FibrillationPRNewsWire • 01/23/23